Short Interest in ENDRA Life Sciences Inc. (NASDAQ:NDRA) Drops By 96.7%

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant decrease in short interest in October. As of October 31st, there was short interest totalling 24,000 shares, a decrease of 96.7% from the October 15th total of 717,700 shares. Based on an average daily volume of 316,200 shares, the days-to-cover ratio is presently 0.1 days. Approximately 4.6% of the company’s shares are short sold.

ENDRA Life Sciences Trading Down 7.7 %

Shares of NDRA stock traded down $0.44 on Thursday, reaching $5.29. 25,931 shares of the stock were exchanged, compared to its average volume of 97,688. The business’s 50 day moving average price is $8.15 and its 200 day moving average price is $7,616.00. ENDRA Life Sciences has a twelve month low of $5.23 and a twelve month high of $4,882.50. The company has a market capitalization of $2.61 million, a price-to-earnings ratio of 0.00 and a beta of 0.74.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($140.00) EPS for the quarter, missing analysts’ consensus estimates of ($122.50) by ($17.50). Equities research analysts forecast that ENDRA Life Sciences will post -387.41 earnings per share for the current year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.